Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

160.26 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 25, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Is This Incredible Dividend Stock Still a Buy Following Its Recent Split?
Johnson & Johnson has completed its separation of Kenvue. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
Pete Davidson Reveals He's Tried Ketamine To Cope With Depression
News of psychedelics and who is using them keeps making headlines. 
Via Benzinga
7 Cash Cow Stocks for Recession-Resilient Dividends
These cash cow stocks are must buys for those looking to craft a recession-resistant portfolio amidst choppy market action. 
Via InvestorPlace
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
This Is What Whales Are Betting On Johnson & Johnson
Via Benzinga
3 Brilliant Blue-Chip Stocks for Lucrative Long-Term Growth
These restaurant and beverage companies are dependable enough to deliver stable earnings and share price gains for many years ahead. 
Via InvestorPlace
When ChatGPT Misses the Mark: 3 Stocks It Got Very Wrong
Generative AI has plenty of potential and utility, but that does not mean they get everything right. Here are three ChatGPT stock mistakes. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Johnson & Johnson Just Cut an Entire Division. Is It Still a Buy?
The change won't have much of an immediate impact for investors either way. 
Via The Motley Fool
2 Dividend Kings That Face Massive Legal Risks
Are the payouts for these two dividend stocks still safe? 
Via The Motley Fool
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?
The healthcare giant's immunology drug Stelara brought in more than $9 billion in revenue last year. 
Via The Motley Fool
Set and Forget: 3 Dividend Stocks Perfect for Your IRA
Here are three of the best dividend stocks that long-term investors looking to build out their IRAs may want to consider. 
Via InvestorPlace
Pharma Giant Johnson & Johnson, Lupin Offer Significant Price Cuts On Tuberculosis Drug
U.S. pharma giant Johnson & Johnson (NYSE: JNJ) and India-based Lupin Limited announced substantial price reductions for their versions of the tuberculosis drug, bedaquiline, to tackle the spread of... 
Via Benzinga
Johnson & Johnson Reveals Updated 2023 Projections After Finalizing Biggest Shake Up In 135 Years
Johnson & Johnson (NYSE: JNJ) has unveiled 2023 projections, predicting double-digit profit growth after its recent spinoff of consumer hea 
Via Benzinga
1 Top Dividend Stock to Buy Hand Over Fist Right Now
Kenvue stands out as a leading dividend provider. 
Via The Motley Fool
Johnson & Johnson Announces Updated Financials and 2023 Guidance Following Completion of the Kenvue Separation
From Johnson & Johnson
Via Business Wire
How To Earn $500 A Month From Johnson & Johnson Stock
J&J's dividend payouts, with a current yield of 2.86%, makes the company a staple in many income-focused portfolios. 
Via Benzinga
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Cannabis Industry's Capital Crunch: Why It Needs More Funds Than Other Industries, Will Fed Legalization Change This?
Recent research conducted by Viridian Capital Advisors reveals that the cannabis sector requires more capital as compared to other similar industries. 
Via Benzinga
Topics Cannabis Economy
Exposures Cannabis Interest Rates
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Biden Targets Cancer, Diabetes Drugs In Controversial Medicare Price Battle
The Centers for Medicare and Medicaid Services unveiled the first ten drugs subject to price negotiations under President Joe Biden's Inflation Reduction Act, including: 
Via Benzinga
Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts
The Biden administration is planning to negotiate the prices of 10 drugs in 2026. 
Via Investor's Business Daily
Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Catalent Inc (NYSE: CTLT), valued at around $8 billion, has finalized a deal with activist investor Elliott Investment Management.  
Via Benzinga
Exposures COVID-19
The 7 Most Promising Blue-Chip Stocks to Own Now
Blue-chip stocks typically represent defensive plays, which makes these mature companies perfect additions to a well-rounded portfolio. 
Via InvestorPlace
7 Reliable Retirement Stocks to Secure a Golden Future
It’s never too early to start thinking about retirement stocks to buy and these compelling ideas could be relevant for the long haul. 
Via InvestorPlace
Topics Retirement
Exposures Pension
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Viridian Chart Of The Week: How Capital Intensive Is Cannabis?
The chart explores the capital intensity of cannabis compared to four other industries thought to be likely suitors for cannabis companies upon federal legalization: Tobacco, Alcoholic Beverages,... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
A Step Closer To Cheaper Drugs For Americans: Price Negotiation And Its Implications
Some of the most frequently prescribed medications in the U.S. might soon become more affordable. 
Via Benzinga
3 Widely Owned Dow Stocks Prominent Billionaires Are Selling
Some of Wall Street's most-successful billionaire money managers are paring down or parting ways with a trio of top-tier companies. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
82 83 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.